March 30 (Reuters) - Halozyme Therapeutics Inc:
* Halozyme provides update on swog collaborative group clinical study
* SWOG phase 1B/2 trial has been temporarily closed to enrollment
* Halozyme - Halozyme is working with SWOG to verify and analyze initial data set following completion of retrospective determination of tumor HA levels
* Halozyme-Addition of PEGPH20 given every two weeks unlikely to demonstrate statistically significant improvement in primary endpoint of overall survival Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.